RLFTY Relief Therapeutics Holding SA (QB)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the Month of May, 2024

Commission File Number: 001-41174

RELIEF THERAPEUTICS Holding SA

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of registrant’s name into English)

Switzerland

(Jurisdiction of incorporation or organization)

Avenue de Sécheron 15

1202 Geneva

Switzerland

Tel: +41 22 545 11 16

(Address of principal executive offices)

Indicate by check mark if the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F     ☒                  Form 40-F     ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)     ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)     ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 8, 2024, Relief Therapeutics Holding SA (the "Company") announced that as part of a leadership transition, (i) Andrew Einhorn, who brings extensive experience from leadership roles within clinical and commercial stage life science companies, joins the Company as its Chief Financial Officer on a part-time basis, (ii) Melinda Keegan, who brings over 20 years of HR life sciences experience and who joined the Company in 2022 on a consulting basis, will join the Company's executive committee in the newly created role of Chief Human Resources Officer, (iii) Giorgio Reiner, who worked with APR Applied Pharma Research SA ("APR") since 2000 and has worked with the Company since its acquisition of APR in 2021, becomes the Company's Chief Scientific Officer, (iv) Paolo Galfetti, the Company's current Chief Operating Officer, transitions to the role of Chief Business Officer, and (v) Vincenzo Gallo, who has worked with APR and the Company and has over 10 years legal expertise in the pharmaceutical industry, joins the Company's executive committee as head of legal and compliance. Additionally, Jeremy Meinen will step down as Chief Financial Officer and transition from the Company in the third quarter of 2024.

On the same date, the Company issued a press release reporting the transition entitled "Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives". A copy of the press release is attached to this Form 6-K as Exhibit 99.1.

INDEX TO EXHIBITS

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RELIEF THERAPEUTICS Holding SA

By: /s/ Michelle Lock

Michelle Lock

Interim Chief Executive Officer

Dated: May 10, 2024

- 3 -

Exhibit 99.1

Ad hoc announcement pursuant to Art. 53 LR

Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives

GENEVA (MAY 8, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its new executive committee strengthening its capabilities with the appointment of several new members, including a chief financial officer, chief human resources officer and head of legal and compliance.

1 / 2

“Following the full company RESET Relief has recently undergone, I am confident that the appointment of this new executive leadership team will accelerate the company’s future success,” said Michelle Lock, interim chief executive officer of Relief. “Their addition to the executive team marks a milestone for Relief and, with an expected cash runway into 2026, the collective experience of our new executive leadership enables us to advance our strategic objectives and uphold our commitment to rare diseases and patient-centric care.”

All executive committee appointments are approved by the Board of Directors and effective immediately.

ABOUT RELIEF

Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief’s portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Relief’s mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website www.relieftherapeutics.com or follow Relief on LinkedIn.

CONTACT:

RELIEF THERAPEUTICS Holding SA

Melinda Keegan

Melinda.keegan@relieftherapeutics.com

DISCLAIMER

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance, or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief’s filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief’s filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.

2 / 2